Advances in MRD Testing for Multiple Myeloma: Impact on Prognosis and Treatment Decisions
This article reviews the role of minimal residual disease (MRD) testing in multiple myeloma (MM), highlighting its association with improved progression-free survival and overall survival. MRD-negative status correlates...
CNP, DipACLM Nurse Practitioner, Massachusetts General Hospital
IsaPd Shows Promise in Dara-R Multiple Myeloma, but Modest PFS Highlights Need for New Therapies
Researchers of a multicenter real-world analysis assessed the efficacy of isatuximab, pomalidomide, and dexamethasone (IsaPd) in 51 patients with multiple myeloma (MM) who were refractory to daratumumab (Dara-R). The study...
Impact of Removing 24-Hour Urine Assessments from IMWG Criteria in Patients With MM Post-ASCT
Researchers of this study analyzed the impact of removing 24-hour urine (24HRU) assessments from International Myeloma Working Group (IMWG) response criteria for patients with multiple myeloma (MM) following autologous stem...
CURATED BY: Laura J. Zitella, MS, RN, ACNP-BC, AOCN
Dexamethasone Dose Reductions in NDMM: No Impact on Survival Outcomes
Dexamethasone is a key component of induction therapy for newly diagnosed multiple myeloma (NDMM), but its use is often associated with toxicities such as hyperglycemia and insomnia....
High-Risk Multiple Myeloma: New Definitions, Diagnostics, and Promising Therapies
Despite significant advancements in multiple myeloma (MM) treatment, a quarter of newly diagnosed patients survive less than three years, particularly those with high-risk MM. This aggressive subset, representing about 20%...
CURATED BY: Laura J. Zitella, MS, RN, ACNP-BC, AOCN
Accurate Diagnostic Model for Newly Diagnosed Multiple Myeloma
Researchers of a recent study aimed to identify clinical laboratory parameters for diagnosing newly diagnosed multiple myeloma (NDMM) and develop a diagnostic model for early and precise detection....
NSD2 Overexpression in t(4;14) Multiple Myeloma Identifies AK2 as a New Therapeutic Target
In a recently published study, researchers revealed that NSD2 overexpression in t(4;14) multiple myeloma (MM) redirects S-adenosylmethionine (SAM) toward excessive methylation of the epigenome, specifically histone H3K36 dimethylation....
